Suppr超能文献

肿瘤微环境限制 IL-10 诱导的多能祖细胞向髓系-淋巴表型分化。

Tumor microenvironment restricts IL-10 induced multipotent progenitors to myeloid-lymphatic phenotype.

机构信息

Department of Medical Microbiology, Immunology, and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL, United States of America.

Simmons Cancer Institute, Southern Illinois University School of Medicine, Springfield, IL, United States of America.

出版信息

PLoS One. 2024 Apr 19;19(4):e0298465. doi: 10.1371/journal.pone.0298465. eCollection 2024.

Abstract

Lymphangiogenesis is induced by local pro-lymphatic growth factors and bone marrow (BM)-derived myeloid-lymphatic endothelial cell progenitors (M-LECP). We previously showed that M-LECP play a significant role in lymphangiogenesis and lymph node metastasis in clinical breast cancer (BC) and experimental BC models. We also showed that differentiation of mouse and human M-LECP can be induced through sequential activation of colony stimulating factor-1 (CSF-1) and Toll-like receptor-4 (TLR4) pathways. This treatment activates the autocrine interleukin-10 (IL-10) pathway that, in turn, induces myeloid immunosuppressive M2 phenotype along with lymphatic-specific proteins. Because IL-10 is implicated in differentiation of numerous lineages, we sought to determine whether this pathway specifically promotes the lymphatic phenotype or multipotent progenitors that can give rise to M-LECP among other lineages. Analyses of BM cells activated either by CSF-1/TLR4 ligands in vitro or orthotopic breast tumors in vivo showed expansion of stem/progenitor population and coincident upregulation of markers for at least four lineages including M2-macrophage, lymphatic endothelial, erythroid, and T-cells. Induction of cell plasticity and multipotency was IL-10 dependent as indicated by significant reduction of stem cell markers and those for multiple lineages in differentiated cells treated with anti-IL-10 receptor (IL-10R) antibody or derived from IL-10R knockout mice. However, multipotent CD11b+/Lyve-1+/Ter-119+/CD3e+ progenitors detected in BM appeared to split into a predominant myeloid-lymphatic fraction and minor subsets expressing erythroid and T-cell markers upon establishing tumor residence. Each sub-population was detected at a distinct intratumoral site. This study provides direct evidence for differences in maturation status between the BM progenitors and those reaching tumor destination. The study results suggest preferential tumor bias towards expansion of myeloid-lymphatic cells while underscoring the role of IL-10 in early BM production of multipotent progenitors that give rise to both hematopoietic and endothelial lineages.

摘要

淋巴管生成是由局部促淋巴管生长因子和骨髓(BM)来源的髓系淋巴管内皮细胞前体(M-LECP)诱导的。我们之前的研究表明,M-LECP 在临床乳腺癌(BC)和实验性 BC 模型中淋巴管生成和淋巴结转移中发挥重要作用。我们还表明,通过顺序激活集落刺激因子-1(CSF-1)和 Toll 样受体-4(TLR4)途径,可以诱导小鼠和人 M-LECP 的分化。这种治疗方法激活了自分泌白细胞介素-10(IL-10)途径,反过来又诱导了骨髓免疫抑制 M2 表型以及淋巴特异性蛋白。由于 IL-10 参与了许多谱系的分化,我们试图确定该途径是否特异性促进了淋巴管表型或多能祖细胞,这些祖细胞可以在其他谱系中产生 M-LECP。对体外通过 CSF-1/TLR4 配体激活或体内原位乳腺肿瘤的 BM 细胞的分析表明,祖细胞/前体细胞群体的扩增以及至少四个谱系的标志物的上调,包括 M2 巨噬细胞、淋巴管内皮细胞、红细胞和 T 细胞。细胞可塑性和多能性的诱导依赖于 IL-10,如用抗 IL-10 受体(IL-10R)抗体处理或源自 IL-10R 敲除小鼠的分化细胞中干细胞标志物和多个谱系标志物的显著减少所表明的那样。然而,在 BM 中检测到的多能性 CD11b+/Lyve-1+/Ter-119+/CD3e+祖细胞似乎在建立肿瘤定植后分裂为主要的髓系-淋巴管细胞亚群和表达红细胞和 T 细胞标志物的较小亚群。每个亚群都在肿瘤内的不同部位被检测到。这项研究为 BM 祖细胞和到达肿瘤目的地的祖细胞之间在成熟状态上的差异提供了直接证据。研究结果表明,肿瘤偏向于优先扩增髓系-淋巴管细胞,同时强调了 IL-10 在早期 BM 产生造血和内皮谱系的多能祖细胞中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/daef/11029653/737ec7b2790c/pone.0298465.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验